Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013

Bipolar Disorders - Tập 15 Số 1 - Trang 1-44 - 2013
Lakshmi N. Yatham1, Sidney H. Kennedy2, Sagar V. Parikh2, Ayal Schaffer2, Serge Beaulieu3, Martin Alda4, Claire O’Donovan4, Glenda MacQueen5, Roger S. McIntyre2, Verinder Sharma6, Arun Ravindran2, L. Trevor Young1, Roumen Milev7, David J. Bond1, Benício N. Frey8, Benjamin I. Goldstein9, Beny Lafer10, Boris Birmaher11, Kyooseob Ha12, Willem A. Nolen13, Michael Berk14,15
1Univ British Columbia, University of British Columbia, Dept Psychiat
2Univ Toronto, University of Toronto, Dept Psychiat
3McGill Univ, McGill University, Dept Psychiat
4Dalhousie Univ, Dalhousie University, Dept Psychiat
5Univ Calgary, University of Calgary, Dept Psychiat
6Univ Western Ontario, University of Western Ontario, Dept Psychiat
7Queens Univ, Queens University - Canada, Dept Psychiat
8McMaster Univ, McMaster University, Dept Psychiat & Behav Neurosci
9Sunnybrook Hlth Sci Ctr, University of Toronto
10Univ Sao Paulo, Universidade de Sao Paulo, Sch Med, Inst Psychiat
11Univ Pittsburgh, University of Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat
12Seoul Natl Univ, Seoul National University, Dept Psychiat
13Interdisciplinary Centre Psychopathology and Emotion regulation (ICPE)
14Deakin Univ, Deakin University, Sch Med
15Univ Melbourne, University of Melbourne, Dept Psychiat

Tóm tắt

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O’Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. 
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. 
Bipolar Disord 2012: 00: 000–000. © 2012 John Wiley & Sons A/S.Published by Blackwell Publishing Ltd.The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009. This third update, in conjunction with the International Society for Bipolar Disorders, reviews new evidence and is designed to be used in conjunction with the previous publications.The recommendations for the management of acute mania remain largely unchanged. Lithium, valproate, and several atypical antipsychotic agents continue to be first‐line treatments for acute mania. Monotherapy with asenapine, paliperidone extended release (ER), and divalproex ER, as well as adjunctive asenapine, have been added as first‐line options.For the management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, as well as olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first‐line options. Lurasidone monotherapy and the combination of lurasidone or lamotrigine plus lithium or divalproex have been added as a second‐line options. Ziprasidone alone or as adjunctive therapy, and adjunctive levetiracetam have been added as not‐recommended options for the treatment of bipolar depression. Lithium, lamotrigine, valproate, olanzapine, quetiapine, aripiprazole, risperidone long‐acting injection, and adjunctive ziprasidone continue to be first‐line options for maintenance treatment of bipolar disorder. Asenapine alone or as adjunctive therapy have been added as third‐line options.

Từ khóa


Tài liệu tham khảo

10.1111/j.1399-5618.2005.00219.x

10.1111/j.1399-5618.2006.00432.x

10.1111/j.1399-5618.2009.00672.x

10.1001/archgenpsychiatry.2011.12

10.1177/070674370905401103

10.1111/j.1399-5618.2009.00786.x

10.1016/j.jad.2011.04.036

10.1001/archgenpsychiatry.2011.113

Stensland MD, 2010, Costs associated with attempted suicide among individuals with bipolar disorder, J Ment Health Policy Econ, 13, 87

10.1016/j.eurpsy.2010.01.001

10.4088/JCP.7075su1c.02

10.1111/j.1399-5618.2010.00856.x

10.4088/JCP.10m06618

10.1186/1471-244X-9-33

10.1177/070674370905400208

10.1001/archgenpsychiatry.2010.15

10.1111/j.1399-5618.2007.00556.x

American Psychiatric Association, 2011, DSM‐5 Development: Bipolar and Related Disorders

10.1192/bjp.bp.109.065524

10.1176/appi.ajp.2009.09030342

10.1016/j.jad.2011.04.026

10.4088/JCP.11m07343

10.1111/j.1399-5618.2010.00852.x

10.1080/00048670902873722

10.1080/16506070802675353

10.3109/09638237.2010.525565

10.1111/j.1399-5618.2011.00949.x

10.1097/00004850-199705000-00009

10.4088/JCP.v65n0315

10.1016/j.pnpbp.2007.09.007

Feifel D, 2011, A naturalistic, single‐blind comparison of rapid dose administration of divalproex ER versus quetiapine in patients with acute bipolar mania, Innov Clin Neurosci, 8, 29

10.1097/00004714-200108000-00006

10.1002/hup.870

10.1111/j.1742-1241.2009.02116.x

10.1590/S1516-44462011000100008

10.4088/JCP.v62n0104

10.1007/s002130000658

10.4088/JCP.v61n1208

10.1097/JCP.0b13e318033bd5e

10.1002/j.1875-9114.1998.tb03827.x

Chouinard G, 1993, A double‐blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms, Can J Psychiatry, 38, S114

10.1177/0091270009347870

10.1016/S0140-6736(11)60873-8

10.1111/j.1399-5618.2010.00798.x

10.1017/S1461145709991246

10.1097/YIC.0b013e3282fd827c

10.1097/YIC.0b013e328333ac1b

10.4088/JCP.v69n1113

10.4088/JCP.v67n1003

10.4088/JCP.08m04960yel

10.1016/j.jad.2010.10.018

10.1192/bjp.bp.108.049965

10.1177/0269881108099418

10.1111/j.1399-5618.2010.00815.x

10.1016/j.jad.2010.06.030

10.1111/j.1399-5618.2009.00748.x

10.1016/j.jad.2009.12.028

10.1111/j.1399-5618.2009.00749.x

10.1016/j.jad.2010.04.005

10.1176/appi.ajp.2008.07101560

10.1185/03007991003779380

10.1016/S0924-9338(10)71430-9

El‐Mallakh RS, 2010, A blinded, randomized comparison of immediate‐release and extended‐release carbamazepine capsules in manic and depressed bipolar subjects, Ann Clin Psychiatry, 22, 3

10.1097/YIC.0b013e328329b199

10.1111/j.1399-5618.2009.00668.x

10.1016/j.eurpsy.2008.12.014

10.1016/j.pnpbp.2008.10.012

Knesevich M, 2009, The Efficacy and Tolerability of Cariprazine in Acute Mania Associated With Bipolar I Disorder: A Phase II Trial [Abstract NR1‐049]

10.1111/j.1440-1819.2010.02066.x

10.1111/j.1399-5618.2006.00363.x

10.4088/JCP.v69n0806

10.1016/j.jad.2010.08.015

10.1111/j.1600-0447.2009.01368.x

10.1097/WNF.0b013e318184fae2

10.1016/j.jad.2010.09.011

Pfizer Inc, 2010, 3‐Week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects

10.1186/1744-859X-8-27

10.4088/JCP.08m04895yel

10.1016/j.jpsychires.2010.05.016

10.1186/1471-244X-11-101

10.1017/S1461145709990344

10.1097/JCP.0b013e3181f15849

10.1192/bjp.bp.107.048504

10.1016/j.jad.2010.10.026

Kemp DE, 2010, Predictive value of early improvement in bipolar depression trials: a post‐hoc pooled analysis of two 8‐week aripiprazole studies, Psychopharmacol Bull, 43, 5

Ketter T, 2011, Presented at 164th Ann Mtg American Psychiatric Association

10.4088/JCP.v66n0710

10.1176/appi.ajp.162.7.1351

10.1097/01.jcp.0000248603.76231.b7

10.4088/JCP.08m04995gre

10.4088/JCP.08m04942gre

10.1016/j.jad.2009.10.007

10.4088/JCP.v67n0703

10.1017/S1461145708009735

10.1001/archpsyc.60.11.1079

10.1016/j.jad.2009.11.008

10.1016/j.jad.2009.10.033

Loebel A, 2012, Lurasidone Monotherapy for the Treatment of Bipolar I Depression: Results of a 6‐Week, Double‐Blind, Placebo‐Controlled Study

Loebel A, 2012, Lurasidone Adjunctive to Lithium or Valproate for the Treatment of Bipolar I Depression: Results of a 6‐Week, Double‐Blind, Placebo‐Controlled

10.4088/JCP.08m04152

10.1111/j.1600-0447.2009.01537.x

10.1192/bjp.bp.112.108357

10.1002/hup.1082

Ahn YM, 2011, Lamotrigine plus quetiapine combination therapy in treatment‐resistant bipolar depression, Ann Clin Psychiatry, 23, 17

10.1097/YCT.0b013e3181b00f1e

10.1016/j.jad.2010.05.008

10.1111/j.1600-0447.2009.01493.x

10.1111/j.1399-5618.2009.00702.x

10.1038/npp.2009.191

10.1016/j.jad.2011.06.005

10.1001/archgenpsychiatry.2010.90

10.4088/JCP.09m05900gry

10.1016/j.biopsych.2009.02.018

Pfizer Inc, 2009, A Six‐Week Study Evaluating the Efficacy and Safety of GEODON in Patients With a Diagnosis of Bipolar I Depression

Pfizer Inc, 2009, A Six‐Week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression

10.4088/JCP.09m05934

10.1517/14656560802504490

10.1016/j.jad.2008.01.004

10.1002/hup.1096

10.1016/j.psychres.2008.05.003

10.4088/JCP.09m05659gre

10.1176/ps.2007.58.1.85

10.4088/JCP.v68n1119

10.1056/NEJMoa064135

10.4088/JCP.v65n1218

10.4088/JCP.09r05385gre

10.1176/appi.ajp.158.6.906

10.1016/S0140-6736(09)60046-5

10.1176/appi.ajp.2008.08050746

10.1111/j.1440-1819.2010.02098.x

10.1176/appi.ajp.163.2.232

10.4088/JCP.v63n0607

Devulapalli KK, 2010, Why do persons with bipolar disorder stop their medication?, Psychopharmacol Bull, 43, 5

10.1016/j.comppsych.2008.06.008

10.1055/s-0030-1263169

10.1016/j.eurpsy.2009.09.003

10.3111/13696998.2011.562265

Bates JA, 2010, Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: a nationwide cross‐sectional survey, PCC J Clin Psychiatry, 12, e1

Gianfrancesco FD, 2009, Association between antipsychotic combination therapy and treatment adherence among individuals with bipolar disorder, Ann Clin Psychiatry, 21, 3

10.1016/j.schres.2009.09.023

10.1016/j.jad.2010.05.021

10.1097/JOM.0b013e3181db811d

10.1186/1744-859X-8-7

10.2146/ajhp080374

10.2165/11535200-000000000-00000

10.3109/15622970903544638

10.1016/j.euroneuro.2010.08.001

Gao K, 2010, Predictors of non‐stabilization during the combination therapy of lithium and divalproex in rapid cycling bipolar disorder: a post‐hoc analysis of two studies, Psychopharmacol Bull, 43, 23

10.1111/j.1399-5618.2010.00826.x

10.1080/15433710903176088

10.4088/JCP.08r04559yel

10.1017/S003329170900590X

10.1001/archpsyc.60.2.145

10.1192/bjp.188.4.313

10.1002/9780470661277.ch32

10.1159/000320738

10.1590/S1516-44462011000200009

10.1192/bjp.bp.107.040485

10.1192/bjp.bp.108.058263

10.1016/j.jad.2009.03.018

10.1177/0269881108093885

10.1017/S1461145711000885

10.1016/S0140-6736(09)61828-6

10.1111/j.1399-5618.2011.00887.x

10.1111/j.1399-5618.2010.00836.x

10.1177/0269881109106900

10.1016/j.euroneuro.2012.03.004

10.1016/j.jad.2012.01.047

10.1016/j.jad.2010.11.037

10.1176/appi.ajp.2008.08020189

10.1016/j.jad.2008.06.001

10.4088/JCP.11m06878

10.1016/j.biopsych.2010.01.015

10.1111/j.1399-5618.2009.00761.x

10.1080/15622970701530917

10.1111/j.1399-5618.2011.00898.x

Carlson B, 2010, Efficacy and Safety of Aripiprazole in Combination With Lamotrigine in a Long‐Term Maintenance Study in Manic or Mixed Subjects With Bipolar I Disorder (CN138‐392) [Abstract]

10.4088/JCP.09m05482yel

10.1002/hup.990

10.1097/JCP.0b013e3181ad223f

10.4088/JCP.07m04022

10.4088/JCP.08m04909gre

10.1016/j.jad.2008.11.003

10.4088/JCP.08m04045

10.1111/j.1440-1819.2009.02026.x

10.1176/appi.ajp.2010.09121816

10.1016/j.jad.2010.07.030

10.1016/j.eurpsy.2009.11.010

10.1016/S1701-2163(16)35082-4

Li X, 2009, Drug Utilization of Pregnancy Category D or X Drugs Among Child‐Bearing Age Women With Depression or Bipolar Disorder in Medicaid [Abstract]

10.1097/AOG.0b013e31816fd910

10.2165/00023210-200822040-00004

10.1056/NEJMoa0907328

10.1016/j.yebeh.2009.09.024

10.1136/bmj.c6581

10.1016/j.reprotox.2008.03.001

10.1177/070674370905400405

10.1097/AOG.0b013e318220edcc

10.1017/S0033291709992194

10.1111/j.1365-2125.2008.03261.x

10.1002/bdra.20641

10.1002/bdrb.20144

10.1007/s00737-008-0044-3

Food and Drug Administration, 2011, Antipsychotic Drugs: Class Labeling Change—Treatment During Pregnancy and Potential Risk to Newborns

Imaz ML, 2011, Obstetrical and neonatal outcomes following prenatal exposure to lithium, Bipolar Disord, 13, 56

10.1007/s00737-010-0151-9

Chessick C, 2011, Sensitivity and specificity of the Mood Disorder Questionnaire in the perinatal population, Bipolar Disord, 13, 35

10.1016/j.jad.2010.11.026

10.1111/j.1399-5618.2009.00685.x

10.1176/appi.ajp.2009.08121902

10.1007/s00737-010-0182-2

10.1016/j.jad.2010.02.123

10.1001/archgenpsychiatry.2008.528

10.1371/journal.pmed.1000013

10.1016/j.jpsychires.2008.11.003

10.1097/01.chi.0000242240.69678.c4

10.1016/S0140-6736(11)60512-6

10.1001/archpsyc.64.9.1032

10.4088/JCP.10m06290

American Psychiatric Association, 2012, DSM‐5 Proposed Revision: Disruptive Mood Dysregulation Disorder

10.1001/archpediatrics.2011.832

10.1111/j.1399-5618.2007.00563.x

10.4088/JCP.10com06220

10.1176/appi.ajp.2009.08101569

10.1001/archpsyc.65.10.1125

10.1176/ajp.2007.164.4.582

10.1016/j.jad.2010.02.120

10.1176/appi.ps.60.8.1098

10.1111/j.1399-5618.2008.00659.x

Evans‐Lacko SE, 2010, Evaluation of guideline‐concordant care for bipolar disorder among privately insured youth, Prim Care Companion J Clin Psychiatry, 12, e1

10.1111/j.1399-5618.2010.00791.x

10.1001/archgenpsychiatry.2012.650

10.1016/j.jad.2009.12.029

10.4088/JCP.09m05845gre

10.1017/S0033291709991437

10.4088/JCP.10m06025yel

10.4088/JCP.09m05585ora

10.4088/JCP.v69n1215

10.1089/cap.2011.0009

10.1001/archpsyc.65.9.1053

10.1111/j.1399-5618.2011.00890.x

West AE, 2009, Child and family‐focused cognitive‐behavioral therapy for pediatric bipolar disorder: pilot study of group treatment format, J Can Acad Child Adolesc Psychiatry, 18, 239

10.1097/chi.0b013e31805c1613

10.1002/da.20668

10.1097/CHI.0b013e3181ae0a08

10.1001/jama.2009.1152

10.1111/j.1399-5618.2009.00728.x

10.1186/1471-244X-9-4

10.1089/cap.2009.0097

10.4088/JCP.08m03538

10.1089/cap.2009.0042

10.1089/cap.2008.0158

10.1089/cap.2008.008

10.1111/j.1399-5618.2009.00750.x

10.1111/j.1399-5618.2010.00850.x

10.1001/archgenpsychiatry.2011.1508

10.1097/01.pra.0000320115.38434.16

10.4088/JCP.09m05164yel

10.4088/JCP.08m04726

10.1111/j.1399-5618.2010.00789.x

10.1111/j.1755-5949.2010.00219.x

10.1111/j.1755-5949.2009.00121.x

10.1111/j.1399-5618.2010.00792.x

10.1089/cap.2008.0107

10.1097/CHI.0b013e31819c55ec

10.1089/cap.2008.0106

10.1089/cap.2008.0162

10.1016/j.jad.2008.11.012

10.1002/gps.2664

10.1097/JGP.0b013e3181b7ef2a

10.1097/JGP.0b013e3181bf9ebd

10.1111/j.1399-5618.2009.00739.x

10.1159/000232974

10.1002/gps.2683

10.1097/JGP.0b013e31819e2d50

10.1111/j.1399-5618.2010.00877.x

10.1016/j.jad.2009.12.004

10.1001/archpsyc.65.11.1331

10.1111/j.1399-5618.2008.00614.x

10.1111/j.1399-5618.2011.00923.x

McIntyre R, 2012, The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid conditions, Ann Clin Psychiatry, 24, 2

10.4088/JCP.08m04586yel

10.1111/j.1399-5618.2010.00823.x

10.1111/j.1399-5618.2009.00735.x

10.1097/PSY.0b013e3181acee26

10.1016/j.jad.2009.06.029

10.1016/j.jad.2010.04.012

10.1007/s12325-010-0072-z

10.1111/j.1399-5618.2009.00730.x

10.1111/j.1399-5618.2010.00855.x

10.1111/j.1399-5618.2011.00932.x

10.1016/j.eurpsy.2011.02.004

10.1111/j.1399-5618.2010.00832.x

10.1016/j.comppsych.2011.10.006

10.1016/j.yebeh.2008.08.002

10.1111/j.1742-1241.2009.02284.x

10.1016/j.comppsych.2010.10.005

10.4088/JCP.09m05198gry

10.1016/j.psychres.2010.07.007

10.1111/j.1399-5618.2009.00664.x

10.4088/JCP.08m04037

10.1111/j.1399-5618.2009.00744.x

10.1016/j.jad.2008.08.019

10.1080/10550880903182994

10.1176/appi.ajp.2010.10030367

10.1111/j.1399-5618.2010.00869.x

10.1016/j.comppsych.2008.06.001

10.1176/appi.ajp.2009.09020218

10.1016/j.jad.2010.06.037

10.1080/15622970701816522

10.1016/j.jpsychires.2009.09.011

McIntyre RS, 2010, Attention‐deficit/hyperactivity disorder in adults with bipolar disorder or major depressive disorder: results from the international mood disorders collaborative project, Prim Care Companion J Clin Psychiatry, 12, e1

10.1111/j.1600-0447.2009.01399.x

10.1016/j.psychres.2007.06.016

10.1016/j.jad.2008.04.010

Kilbourne AM, 2008, Improving medical and psychiatric outcomes among individuals with bipolar disorder: a randomized controlled trial, Psychiatr Serv, 59, 760, 10.1176/ps.2008.59.7.760

10.1097/01.pra.0000398419.82362.32

10.1016/j.jpsychires.2011.01.019

10.1007/s11695-011-0373-6

10.1016/j.drugalcdep.2009.04.018

10.1016/j.jad.2010.10.040

10.4088/JCP.v69n0502

10.1111/j.1530-0277.2010.01270.x

10.1111/j.1530-0277.2009.01024.x

10.4088/JCP.v69n0808

10.1097/JCP.0b013e31814db4c4

10.1016/j.jad.2008.11.011

10.1089/cap.2009.0037

10.1016/j.jad.2008.10.005

10.4088/PCC.08m00659

10.1016/j.jad.2009.11.014

10.4088/JCP.08m04854yel

10.1016/S0165-0327(01)00435-9

10.1111/j.1399-5618.2008.00629.x

Young AH, 2010, The efficacy of quetiapine monotherapy in bipolar II depression: combined data from the BOLDER and EMBOLDEN studies, Bipolar Disord, 12, 58

10.4088/JCP.09m05570gre

Sachs G, 2001, Divalproex Sodium Versus Placebo in the Treatment of Bipolar Depression [Abstract]

10.1016/j.jad.2009.10.021

10.1111/j.1399-5618.2007.00500.x

10.1097/JCP.0b013e3181da5300

10.1016/j.jad.2008.03.029

10.1111/j.1600-0447.2009.01462.x

10.1016/j.jad.2009.01.014

10.1016/j.jad.2010.08.001

10.1016/j.jad.2008.12.010

10.1016/j.jad.2008.03.023

10.1016/j.pnpbp.2010.07.020

10.1016/j.jad.2008.01.029

10.1016/j.jad.2008.01.017

10.1016/j.jpsychires.2010.02.005

10.1097/01.yic.0000171519.64080.c9

10.1176/appi.ajp.2009.09020284

10.1038/npp.2010.122

10.4088/JCP.v69n1009

10.1176/appi.ajp.2010.09060880

10.1097/YCT.0b013e3181dbf797

10.1111/j.1600-0447.2010.01638.x

10.1016/j.jad.2007.07.027

10.1176/appi.ajp.2007.05122032

10.1016/j.jad.2010.03.028

10.1037/a0023973

10.1001/archpsyc.64.5.543

10.1176/appi.ajp.2010.09071011

10.4088/JCP.v68n0519

10.1177/0269881108097715

10.1111/j.1399-5618.2009.00737.x

10.1016/j.clinthera.2009.07.004

10.1016/j.jad.2009.10.023

10.2165/11589060-000000000-00000

Bobo WV, 2011, Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: a randomized, open comparison in outpatients with bipolar depression, Ann Clin Psychiatry, 23, 193

10.1016/j.euroneuro.2011.06.005

Kemp DE, 2011, Long‐term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine, Bipolar Disord, 13, 60

10.1001/jama.2009.1549

Gillhoff K, 2010, Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial, Prim Care Companion J Clin Psychiatry, 12, pii

10.1016/j.genhosppsych.2010.09.005

10.4088/JCP.09m05159gre

10.1016/j.jad.2009.12.011

10.1080/00048670802534341

10.1111/j.1399-5618.2010.00814.x

10.1016/S0140-6736(11)61516-X

10.1176/appi.ajp.2011.11010163

10.1017/S0033291707001675

10.1037/a0016277

10.1111/j.1600-0447.2008.01320.x

10.1016/j.comppsych.2010.12.009

10.1016/j.schres.2009.04.020

10.1097/YIC.0b013e32834e3bea

Burdick K, 2011, Cognitive enhancement in euthymic bipolar patients with pramipexole: a placebo‐controlled adjunctive trial, Bipolar Disord, 13, 33

10.1097/JCP.0b013e3181a497d7

10.1097/JCP.0b013e3181845610

10.1016/j.pnpbp.2009.06.010

10.1097/YIC.0b013e32832775fe

Food and Drug Administration, 2011, FDA Drug Safety Communication: Serious Allergic Reactions Reported With the Use of Saphris (Asenapine Maleate)

Cazorla P, 2011, Incidence, onset, and duration of treatment emergent somnolence with asenapine in patients with schizophrenia or bipolar disorder, Bipolar Disord, 13, 34

10.2190/PM.39.4.h

10.1177/0269881109348157

10.1097/YIC.0b013e3282f2b3bb

10.1016/j.jad.2010.11.019

Thông tin
Thông tin xuất bản

Bipolar Disorders

Tập 15 Số 1

1-44

Thông tin tác giả